Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00992030 | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma | terminated | Phase 3 | 112 | Fondazione MichelangeloOTHER | 2 | Aug 19, 2021 | clinicaltrials |
| NCT00003337 | Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma | unknown | Phase 3 | 100 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT00003338 |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma |
| unknown |
| Phase 2 / Phase 3 |
| 60 |
| Gilead SciencesINDUSTRY |
| 5 |
| Aug 16, 2021 |
| clinicaltrials |
| NCT05006469 | Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 10 | Liao AijunOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT00369564 | Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer | completed | Phase 3 | 250 | University of South FloridaOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04910594 | Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma | unknown | Phase 3 | 130 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04980859 | Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation | unknown | Phase 3 | 45 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 28, 2021 | clinicaltrials |
| NCT01122472 | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP(REMARC) | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 9 | Jul 26, 2021 | clinicaltrials |
| NCT03123939 | Phase III B in Acute Lymphoblastic Leukemia | completed | Phase 3 | 69 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 21, 2021 | clinicaltrials |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | terminated | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 20, 2021 | clinicaltrials |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn | Phase 3 | 0 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT01817075 | Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant | completed | Phase 3 | 177 | Children's Oncology GroupNETWORK | 3 | Jun 22, 2021 | clinicaltrials |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma(FiTNEss) | unknown | Phase 3 | 740 | University of LeedsOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT00103285 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 5,377 | Children's Oncology GroupNETWORK | 5 | Jun 14, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT00052936 | Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | completed | Phase 3 | 1,506 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 2 | May 18, 2021 | clinicaltrials |
| NCT00053768 | Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 3 | 392 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 2 | May 18, 2021 | clinicaltrials |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | completed | Phase 3 | 329 | Seagen Inc.INDUSTRY | 13 | May 14, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT04880746 | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | unknown | Phase 3 | 266 | Ruijin HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | unknown | Phase 3 | 319 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT00003056 | Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | terminated | Phase 3 | 105 | Baxalta now part of ShireINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | completed | Phase 3 | 637 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2021 | clinicaltrials |
| NCT00075725 | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | completed | Phase 3 | 3,154 | Children's Oncology GroupNETWORK | 5 | Apr 27, 2021 | clinicaltrials |
| NCT00671034 | Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | completed | Phase 3 | 166 | Children's Oncology GroupNETWORK | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT | withdrawn | Phase 3 | 0 | Loyola UniversityOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02112175 | Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM(ARUMM) | completed | Phase 3 | 46 | CelgeneINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | completed | Phase 3 | 250 | The Lymphoma Academic Research OrganisationOTHER | 2 | Apr 13, 2021 | clinicaltrials |
| NCT02260804 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | completed | Phase 3 | 258 | CelltrionINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00302003 | Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | completed | Phase 3 | 287 | Children's Oncology GroupNETWORK | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT04799314 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT | unknown | Phase 3 | 132 | Ruijin HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02085655 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | unknown | Phase 3 | 264 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT00278421 | Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 3 | 592 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 3 | Mar 11, 2021 | clinicaltrials |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment(PO-3887) | terminated | Phase 3 | 9 | Fondazione EMN Italy OnlusOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | completed | Phase 3 | 181 | Pharmacyclics LLC.INDUSTRY | 9 | Mar 3, 2021 | clinicaltrials |
| NCT00003650 | Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma | completed | Phase 3 | 179 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | completed | Phase 3 | 475 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 15, 2021 | clinicaltrials |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)(H11) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04342936 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 3 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma(H10) | unknown | Phase 3 | 1,952 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00004031 | SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 3 | 397 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 2, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
| NCT00452439 | A Study of Actonel for the Prevention of Bone Loss | completed | Phase 3 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)(Javelin DLBCL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT01371656 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | completed | Phase 3 | 624 | Children's Oncology GroupNETWORK | 2 | Dec 7, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2021source: clinicaltrials